Nanobac Pharmaceuticals Incorporated (NNBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2005 | 03-2005 | 12-2004 | 09-2004 | 06-2004 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 20 | 10 | 10 | 10 | 20 |
| Receivables | 6 | 10 | 3 | 2 | 10 |
| Inventories | 70 | 70 | 70 | 20 | 10 |
| Other current assets | 34 | 40 | 27 | 8 | 30 |
| TOTAL | $130 | $130 | $110 | $40 | $70 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 9,040 | 9,250 | 9,430 | 10,990 | 11,210 |
| TOTAL | $9,040 | $9,250 | $9,430 | $10,990 | $11,210 |
| Total Assets | $9,310 | $9,540 | $9,680 | $11,170 | $11,420 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 420 | 620 | 640 | 540 | 660 |
| Accrued Expenses | 550 | 730 | 380 | 660 | 710 |
| Other current liabilities | 10 | 10 | 10 | 10 | 10 |
| TOTAL | $2,510 | $2,110 | $1,300 | $1,260 | $8,640 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 2,860 | 2,490 | 2,260 | 0 | 0 |
| TOTAL | $2,860 | $2,490 | $2,260 | $N/A | $N/A |
| Total Liabilities | $5,370 | $4,600 | $3,570 | $1,260 | $8,640 |
| Shareholders' Equity | |||||
| Common Shares | 16,300 | 16,300 | 16,290 | 22,380 | 13,630 |
| Retained earnings | -15,870 | -13,830 | -13,040 | -11,830 | -10,830 |
| Other shareholders' equity | 0 | -1,050 | -670 | -640 | -20 |
| TOTAL | $3,930 | $4,930 | $6,110 | $9,910 | $2,780 |
| Total Liabilities And Equity | $9,300 | $9,530 | $9,680 | $11,170 | $11,420 |